1 Global CMO of Sterile Injectable Drugs Market 2020-2030

1.1 Executive Summary

1.2 Why You Should Read This Report

1.3 What This Report Delivers

1.4 Key Questions Answered by This Analytical Report Include:

1.5 Who is This Report For?

1.6 Methodology

1.7 Frequently Asked Questions (FAQs)

1.8 Associated Visiongain Reports

1.9 About Visiongain

2 Introduction to the CMO of Sterile Injectable Drugs Market

2.1 Opportunities for the CMO of Sterile Injectable

2.2 CMO of Sterile Injectable Definition

2.3 CMO of Sterile Injectable Overview

2.3.1 Executive Summary

2.3.1 CMO of Sterile Injectable Segmentation

2.3.2 CMO of Sterile Injectable, By Large Molecule

2.3.3 CMO of Sterile Injectable, By Molecule Type

2.3.4 CMO of Sterile Injectable, By Container Type

3 Market Overview

3.1 Market Drivers

3.1.1 Increasing Prevalence of Chronic Diseases

3.1.2 Lucrative demand for biologics

3.1.3 Patent Cliff Till 2022

3.2 Market Restraints

3.2.1 Stringent Regulatory Requirements

3.3 Market Opportunities

3.3.1 Emerging Business Segments and Economies

3.4 Porter’s five forces

3.4.1 Bargaining Power of Buyers (High)

3.4.2 Bargaining Power of Suppliers (Low)

3.4.3 Threat of Substitutes (Low)

3.4.4 Threat of New Entrants (Medium)

3.4.5 Industry Rivalry (High)

4 Global CMO of Sterile Injectable Drugs Market by Molecule Type

4.1 Small Molecule Submarket Forecast 2020-2030

4.2 Large Molecule Submarket Forecast 2020-2030

5 Global CMO of Sterile Injectable Drugs Market by Large Molecule

5.1 Monoclonal antibodies Submarket Forecast 2020-2030

5.2 Insulin Submarket Forecast 2020-2030

5.3 Cytokines Submarket Forecast 2020-2030

5.4 Vaccines Submarket Forecast 2020-2030

5.5 Blood factors Submarket Forecast 2020-2030

5.6 Others Submarket Forecast 2020-2030

6 Global CMO of Sterile Injectable Drugs Market by Application

6.1 Cancer Submarket Forecast 2020-2030

6.2 Diabetes Submarket Forecast 2020-2030

6.3 Cardiovascular diseases Submarket Forecast 2020-2030

6.4 CNS Submarket Forecast 2020-2030

6.5 Infectious Submarket Forecast 2020-2030

6.6 Others Submarket Forecast 2020-2030

7 Global CMO of Sterile Injectable Drugs Market by Container

7.1 Bottles Submarket Forecast 2020-2030

7.2 Ampoules Submarket Forecast 2020-2030

7.3 Vials Submarket Forecast 2020-2030

7.4 Prefilled Syringe Submarket Forecast 2020-2030

7.5 Bags Submarket Forecast 2020-2030

8 Regional and Leading National CMO of Sterile Injectable Forecasts 2020-2030

8.1 Global CMO of Sterile Injectable by National Market Share Forecast 2020-2030

8.2 North America CMO of Sterile Injectable Forecast 2020-2030

8.2.1 U.S. CMO of Sterile Injectable Forecast 2020-2030

8.2.2 Canada CMO of Sterile Injectable Forecast 2020-2030

8.3 Europe CMO of Sterile Injectable Forecast 2020-2030

8.3.1 Germany CMO of Sterile Injectable Forecast 2020-2030

8.3.2 France CMO of sterile injectable Forecast 2020-2030

8.3.3 UK CMO of sterile injectable Forecast 2020-2030

8.3.4 Italy CMO of Sterile Injectable Forecast 2020-2030

8.3.5 Spain CMO of sterile injectable Forecast 2020-2030

8.3.6 Rest of Europe CMO of sterile injectable Forecast 2020-2030

8.4 Asia Pacific CMO of sterile injectable Forecast 2020-2030

8.4.1 China CMO of sterile Injectable Forecast 2020-2030

8.4.2 Japan CMO of Sterile Injectable Forecast 2020-2030

8.4.3 India CMO of sterile injectable Forecast 2020-2030

8.4.4 Rest of APAC CMO of sterile injectable Forecast 2020-2030

8.5 Latin America CMO of sterile injectable Forecast 2020-2030

8.6 Middle East & Africa CMO of sterile injectable Forecast 2020-2030

9 Leading Companies in the CMO of sterile injectable

9.1 Jubilant Life Sciences Limited

9.1.1 Jubilant Life Sciences Limited Total Company Sales 2016 - 2019

9.1.2 Jubilant Life Sciences Limited Products / Services

9.1.3 Jubilant Life Sciences Limited Mergers & Acquisitions (M&A) Activity

9.1.4 Jubilant Life Sciences Limited CMO outlook

9.2 Boehringer Ingelheim

9.2.1 Boehringer Ingelheim Total Company Sales 2016 - 2018

9.2.2 Boehringer Ingelheim Products / Services

9.2.3 Boehringer Ingelheim Mergers & Acquisitions (M&A) Activity

9.2.4 Boehringer Ingelheim CMO outlook

9.3 Recipharm AB

9.3.1 Recipharm AB Total Company Sales 2016 - 2018

9.3.2 Recipharm AB Products / Services

9.3.3 Recipharm AB Mergers & Acquisitions (M&A) Activity

9.3.4 Recipharm AB CMO outlook

9.4 Lonza

9.4.1 Lonza Total Company Sales 2016 - 2019

9.4.2 Lonza Products / Services

9.4.3 Lonza Mergers & Acquisitions (M&A) Activity

9.4.4 Lonza CMO outlook

9.5 Patheon, Inc (Parent organization: Thermo Fischer company)

9.5.1 Patheon, Inc Total Company Sales 2016 - 2019

9.5.2 Patheon, Inc Products / Services

9.5.3 Patheon, Inc Mergers & Acquisitions (M&A) Activity

9.5.4 Patheon, Inc CMO outlook

9.6 Catalent, Inc

9.6.1 Catalent, Inc Total Company Sales 2016 - 2019

9.6.2 Catalent, Inc. Products / Services

9.6.3 Catalent, Inc. Mergers & Acquisitions (M&A) Activity

9.6.4 Catalent, Inc. CMO outlook

9.7 Almac Group

9.7.1 Almac Group Total Company Sales 2018

9.7.2 Almac Group Products / Services

9.7.3 Almac Group Mergers & Acquisitions (M&A) Activity

9.7.4 Almac Group CMO outlook

9.8 Siegfried Holding AG

9.8.1 Siegfried Holding AG Total Company Sales 2016 - 2019

9.8.2 Siegfried Holding AG Products / Services

9.8.3 Siegfried Holding AG Mergers & Acquisitions (M&A) Activity

9.8.4 Siegfried Holding AG CMO outlook

9.9 Consort Medical, Plc.

9.9.1 Consort Medical, Plc. Total Company Sales 2016 - 2018

9.9.2 Consort Medical, Plc. Products / Services

9.9.3 Consort Medical, Plc. Mergers & Acquisitions (M&A) Activity

9.9.4 Consort Medical, Plc.CMO outlook

9.10 Aenova Group

9.10.1 Aenova Group Products / Services

9.11 Grifols SA

9.11.1 Grifols SA Total Company Sales 2016 - 2019

9.11.2 Grifols SA Products / Services

9.11.3 Grifols SA Mergers & Acquisitions (M&A) Activity

9.12 Famar Health Care Services

9.12.1 Famar Health Care Services Products / Services

9.12.2 Famar Health Care Services Mergers & Acquisitions (M&A) Activity

9.13 Evonik Industries AG

9.13.1 Evonik Industries AG Total Company Sales 2016 - 2019

9.13.2 Evonik Industries AG Products / Services

9.13.3 Evonik Industries AG Mergers & Acquisitions (M&A) Activity

9.14 Baxter Biopharma Solutions

9.14.1 Baxter Biopharma Solutions Total Company Sales 2016 - 2019

9.14.2 Baxter Biopharma Solutions Products / Services

9.14.3 Baxter Biopharma Mergers & Acquisitions (M&A) Activity

9.15 Pfizer CentreOne

9.15.1 Pfizer CentreOne Total Company Sales 2016 - 2019

9.15.2 Pfizer CentreOne Products / Services

9.15.3 Pfizer CentreOne Mergers & Acquisitions (M&A) Activity

10 Conclusions and Recommendations

10.1 Associated Visiongain Reports

Appendix A

About Visiongain

Appendix B

Visiongain report evaluation form

List of Tables

Table 1. Executive Summary

Table 2. CVD Total Costs Through 2035

Table 3. HIV Vaccines, Passive Immunization, and Antibody Gene Transfer Pipeline

Table 4. List of Biologics and Growth Rate (%)

Table 5. Drugs Going Generic in 2020-2024

Table 6. CDMO PE Buyouts

Table 7. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule Type (US$ million, AGR %)

Table 8. Small Molecule Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 9. Large Molecule Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 10. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030, Large Molecule (US$ million, AGR %)

Table 11. Global Monoclonal Antibodies Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 12. Insulin Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 13. Global Cytokines Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 14. Global Vaccines Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 15. Global Blood factors Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 16. Global Others Sub Market Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 17. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)

Table 18. U.S. Perspective on the Highest-Selling Drugs in 2018

Table 19. Cancer Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 20. Diabetes Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 21. Cardiovascular diseases Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 22. CNS Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 23. Infectious Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 24. Others Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 25. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)

Table 26. Bottles Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 27. Ampoules Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 28. Vials Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 29. Prefilled Syringe Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 30. Bags Revenue Forecast 2020-2030 (US$ million, AGR %)

Table 31. The North American CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (US$ million, AGR %)

Table 32. The North America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)

Table 33. The North American CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)

Table 34. The North American CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)

Table 35. U.S. CMO of Sterile Injectable Forecast 2020-2030 (US$ million, AGR %)

Table 36. Canada CMO of Sterile Injectable Forecast 2020-2030 (US$ million, AGR %)

Table 37. Europe CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (US$ million, AGR %)

Table 38. Europe CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)

Table 39. Europe CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)

Table 40. Europe CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030, by Container (US$ million, AGR %)

Table 41. Germany CMO of sterile injectable Forecast (US$ million, AGR %)

Table 42. France CMO of sterile injectable Forecast (US$ million, AGR %)

Table 43. UK CMO of sterile injectable Forecast (US$ million, AGR %)

Table 44. Italy CMO of sterile injectable Forecast (US$ million, AGR %)

Table 45. Spain CMO of sterile injectable Forecast (US$ million, AGR %)

Table 46. Rest of Europe CMO of sterile injectable Forecast (US$ million, AGR %)

Table 47. Asia Pacific CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (US$ million, AGR %)

Table 48. Asia Pacific CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)

Table 49. Asia Pacific CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)

Table 50. Asia Pacific CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)

Table 51. China CMO of Sterile Injectable Forecast (US$ million, AGR %)

Table 52. Japan CMO of sterile injectable Forecast (US$ million, AGR %)

Table 53. India CMO of sterile injectable Forecast (US$ million, AGR %)

Table 54. Rest of APAC CMO of sterile injectable Forecast (US$ million, AGR %)

Table 55. Latin America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (US$ million, AGR %)

Table 56. Latin America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)

Table 57. Latin America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)

Table 58. Latin America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)

Table 59. Middle East & Africa CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (US$ million, AGR %)

Table 60. Middle East & Africa CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)

Table 61. Middle East & Africa CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)

Table 62. Middle East & Africa CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)

Table 63. Jubilant Life Sciences Limited Company Overview

Table 64. Boehringer Ingelheim company overview

Table 65. Recipharm AB company overview

Table 66. Lonza company overview

Table 67. Patheon, Inc. company overview ( Thermo Fischer company)

Table 68. Catalent, Inc. company overview

Table 69. Almac Group company overview

Table 70. Almac Group Total Company Sales 2018

Table 71. Siegfried Holding AG company overview

Table 72. Consort Medical, Plc. Company overview

Table 73. Jubilant Life Sciences Limited company overview

Table 74. Grifols SA company overview

Table 75. Famar Health Care Services company overview

Table 76. Famar Health Care Services Total Company Sales 2017

Table 77. Evonik Industries AG company overview

Table 78. Baxter Biopharma Solutions company overview

Table 79. Pfizer CentreOne company overview

List of Figures

Figure 1. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 (US$ million, AGR%)

Figure 2. Objectives and Relationship of Customer and CMO

Figure 3. CMO of Sterile Injectable Segmentation

Figure 4. CMO of sterile injectable DRO

Figure 5. Worldwide Sales at Risk from Patent Expiration (2019-2024)

Figure 6. Top 10 Therapy Areas in 2024, Market Share & Sales Growth

Figure 7. Survey of U.S. Based Companies: Destination for International Outsourcing “Strong Likelihood” or “Likelihood” for the Next 5 Years

Figure 1. CMO of Sterile Injectable Drugs Market Porter’s Five Forces

Figure 2. CMO of Sterile Injectable Drugs Market by Molecule Type

Figure 3. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million)

Figure 4. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (%)

Figure 5. Small Molecule Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 6. Large Molecule Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 7. CMO of Sterile Injectable Drugs Market by Large Molecule

Figure 8. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecules (US$ million)

Figure 9. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (%)

Figure 10. Global Monoclonal antibodies Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 11. Insulin Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 12. Global Cytokines Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 13. Global Vaccines Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 14. Global Blood Factors Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 15. Global Blood Factors Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 16. CMO of Sterile Injectable Drugs Market by Application

Figure 17. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million)

Figure 18. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (%)

Figure 19. Cancer Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 20. Diabetes Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 21. Cardiovascular diseases Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 22. CNS Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 23. Infectious Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 24. Others Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 25. CMO of Sterile Injectable Drugs Market by Container

Figure 26. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million)

Figure 27. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Containers (%)

Figure 28. Bottles Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 29. Ampoules Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 30. Vials Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 31. Prefilled Syringe Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 32. Bags Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 8. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Containers (%)

Figure 9. The North America CMO of Sterile Injectable Forecast 2020-2030 (US$ million, AGR %)

Figure 10. U.S. CMO of Sterile Injectable Forecast 2020-2030 (US$ million, AGR %)

Figure 11. Canada CMO of sterile injectable Forecast 2020-2030 (US$ million, AGR %)

Figure 12. Europe CMO of Sterile Injectable Forecast 2020-2030 (US$ million, AGR %)

Figure 13. Germany CMO of sterile injectable Forecast (US$ million, AGR %)

Figure 14. France CMO of sterile injectable Forecast (US$ million, AGR %)

Figure 15. UK CMO of sterile injectable Forecast (US$ million, AGR %)

Figure 16. Italy CMO of sterile injectable Forecast (US$ million, AGR %)

Figure 17. Spain CMO of sterile injectable Forecast (US$ million, AGR %)

Figure 18. Rest of Europe CMO of sterile injectable Forecast (US$ million, AGR %)

Figure 19. Asia Pacific CMO of sterile injectable Forecast 2020-2030 (US$ million, AGR %)

Figure 20. China CMO of Sterile Injectable Forecast (US$ million, AGR %)

Figure 21. Japan CMO of sterile injectable Forecast (US$ million, AGR %)

Figure 22. India CMO of sterile injectable Forecast (US$ million, AGR %)

Figure 23. Rest of APAC CMO of sterile injectable Forecast (US$ million, AGR %)

Figure 24. Latin America CMO of Sterile Injectable Forecast 2020-2030 (US$ million, AGR %)

Figure 25. Middle East & Africa CMO of sterile injectable Forecast 2020-2030 (US$ million, AGR %)

Figure 26. Jubilant Life Sciences Limited Total Company Sales 2016-2019

Figure 27. Total Company Sales by business segment, 2019

Figure 28. Products / Services

Figure 29. Mergers & Acquisitions (M&A) Activity

Figure 30. Boehringer Ingelheim Total Company Sales 2016-2018

Figure 31. Total Company Sales by business segment, 2019

Figure 32. Products / Services

Figure 33. Mergers & Acquisitions (M&A) Activity

Figure 34. Recipharm AB Total Company Sales 2016-2018

Figure 35. Total Company Sales by business segment, 2018

Figure 36. Products / Services

Figure 37. Mergers & Acquisitions (M&A) Activity

Figure 38. Lonza Total Company Sales 2016-2019

Figure 39. Total Company Sales by business segment, 2019

Figure 40. Products / Services

Figure 41. Mergers & Acquisitions (M&A) Activity

Figure 42. Patheon, Inc. Total Company Sales 2016-2019

Figure 43. Total Company Sales by business segment, 2019

Figure 44. Products / Services

Figure 45. Mergers & Acquisitions (M&A) Activity

Figure 46. Catalent, Inc. Total Company Sales 2016-2019

Figure 47. Total Company Sales by business segment, 2019

Figure 48. Products / Services

Figure 49. Mergers & Acquisitions (M&A) Activity

Figure 50. Products / Services

Figure 51. Mergers & Acquisitions (M&A) Activity

Figure 52. Siegfried Holding AG Total Company Sales 2016-2019

Figure 53. Products / Services

Figure 54. Mergers & Acquisitions (M&A) Activity

Figure 55. Consort Medical, Plc. Total Company Sales 2016-2018

Figure 56. Total Company Sales by business segment, 2018

Figure 57. Products / Services

Figure 58. Mergers & Acquisitions (M&A) Activity

Figure 59. Products / Services

Figure 60. Grifols SA Total Company Sales 2016-2019

Figure 61. Total Company Sales by business segment, 2019

Figure 62. Products / Services

Figure 63. Mergers & Acquisitions (M&A) Activity

Figure 64. Products / Services

Figure 65. Mergers & Acquisitions (M&A) Activity

Figure 66. Evonik Industries AG Total Company Sales 2016-2019

Figure 67. Total Company Sales by business segment, 2019

Figure 68. Products / Services

Figure 69. Mergers & Acquisitions (M&A) Activity

Figure 70. Baxter Biopharma Solutions Total Company Sales 2016-2019

Figure 71. Total Company Sales by business segment, 2019

Figure 72. Products / Services

Figure 73. Mergers & Acquisitions (M&A) Activity

Figure 74. Pfizer CentreOne Total Company Sales 2016-2019

Figure 75. Total Company Sales by business segment, 2019

Figure 76. Products / Services

Figure 77. Mergers & Acquisitions (M&A) Activity

Figure 78. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 (US$ million, AGR %)

Figure 79. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (US$ million)

Figure 80. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (%)

Figure 81. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million)

Figure 82. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (%)

Figure 83. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million)

Figure 84. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (%)

Figure 85. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million)

Figure 86. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Containers (%)